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Abstract
Introduction: Puumala hantavirus (PUUV) causes a hemorrhagic fever with renal syndrome called nephropathia epidemica
(NE). The aim of the present study was to evaluate plasma cell-free DNA (cf-DNA) levels and urinary cf-DNA excretion in
acute NE as well as their associations with the severity of the disease.
Methods: Total plasma cf-DNA was quantified directly in plasma of 61 patients and urine of 20 patients with acute NE. We
also carried out a qualitative high-sensitivity lab-on-a-chip DNA assay in 20 patients to elucidate the appearance of cf-DNA
in plasma and urine.
Results: The maximum plasma cf-DNA values taken during acute NE were significantly higher than the control values taken
after the hospitalization period (median 1.33 mg/ml, range 0.94–3.29 mg/ml vs. median 0.77 mg/ml, range 0.55–0.99 mg/ml,
P,0.001). The maximum plasma cf-DNA levels correlated positively with maximum blood leukocyte count (r= 0.388,
P= 0.002) and the length of hospital stay (r= 0.376, P= 0.003), and inversely with minimum blood platelet count (r=20.297,
P= 0.020). Qualitative analysis of plasma cf-DNA revealed that in most of the patients cf-DNA displayed a low-molecular
weight appearance, corresponding to the size of apoptotic DNA (150–200 bp). The visually graded maximum cf-DNA band
intensity correlated positively with the maximum quantity of total plasma cf-DNA (r= 0.513, P= 0.021). Maximum urinary
excretion of cf-DNA in turn was not markedly increased during the acute phase of NE and did not correlate with any of the
variables reflecting severity of the disease or with the maximum plasma cf-DNA level.
Conclusions: The plasma levels of cf-DNA are elevated during acute PUUV infection and correlate with the apoptotic cf-
DNA-band intensity. The plasma cf-DNA concentration correlates with some variables reflecting the severity of the disease.
The urinary excretion of cf-DNA does not reflect the degree of inflammation in the kidney.
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Introduction
Puumala hantavirus (PUUV) is a rodent-borne zoonotic virus
carried by the bank vole, Myodes glareolus [1]. PUUV causes a mild
hemorrhagic fever with renal syndrome called nephropathia
epidemica (NE) [2]. Numerous hantaviruses cause hemorrhagic
fever with renal syndrome in Eurasia and hantavirus cardiopul-
monary syndrome in the Americas [2]. In Finland, 1000–3000
serological NE diagnoses are made annually (http://www3.ktl.fi).
The severity of PUUV infection varies from subclinical disease
to rare fatal cases [3]. Host genetics have been shown to influence
the clinical picture [4]. After an incubation period of 2–6 weeks,
the disease begins with sudden high fever, headache, back and
abdominal pains, nausea and visual disturbances [5–6]. Signs of
renal involvement are proteinuria and hematuria, as well as
oliguria followed by polyuria [5–6]. Five per cent of hospitalized
patients need transient hemodialysis treatment [2]. Typical
laboratory findings during the acute phase are leukocytosis,
thrombocytopenia, anemia, and elevation of plasma C-reactive
protein (CRP) and creatinine levels [6]. Radiological pulmonary
manifestations have been detected in about one-third of NE
patients [7–9]. In addition, over half of patients have abnormal
cardiac findings [10].
The pathogenesis of NE is not completely understood. An
important feature in hantaviral infections is capillary leakage due
to increased capillary permeability. The mechanisms behind this
phenomenon are unclear, but complement activation may be
involved [11–13]. Immunological responses rather than direct
cytotoxicity of the virus have been suggested to be important in the
pathogenesis of hantaviral infections. One reason for this
hypothesis is that hantaviruses are considered noncytopathic
[14–15], although under certain conditions Tula hantavirus
induces apoptosis in cultured cells [16–17]. Increased cytokine
levels have been found in the plasma, urine and tissues in patients
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with hantaviral infection [18–21], and in our previous study, high
interleukin (IL)-6 levels also associated with a clinically severe
course of NE [22]. In addition, high levels of indoleamine 2,3
dioxygenase (IDO) and pentraxin-3 (PTX3), elements of the
innate immunity, were associated with a clinically severe NE in
our previous studies [23–24]. Although no direct viral cytopathy
has been detected, increased levels of serum lactate dehydroge-
nase, aspartate aminotransferase, and alanine aminotransferase
have been observed in patients with hantaviral infection,
indicating that the cellular membrane integrity is disturbed [25].
A recent study in PUUV-infected patients showed that epithelial
cell apoptosis is induced during acute infection and suggests that
the tissue damage is due to immune reaction [26].
Circulating cell-free DNA (cf-DNA) has recently been studied in
various acute and chronic clinical disorders. Elevated levels of cf-
DNA have been reported in cancer, autoimmune diseases, stroke,
myocardial infarction, trauma patients and sepsis [27–34]. It has
also been proposed that cf-DNA could be used as a predictor of
outcome or disease severity in these conditions [35]. Detectable
levels of cf-DNA are present also in the plasma of healthy
individuals, but the concentrations are low [36]. However, a
recent study showed cf-DNA concentrations to be elevated in
elderly women [37]. The current view is that in clinical conditions
cf-DNA originates from apoptotic or necrotic cells and therefore
reflects the amount of cellular damage [27].
Studies on plasma cf-DNA in viral infections are scarce and
urine levels of cf-DNA have not previously been studied in
infectious diseases. In the present study, our aim was to assess cf-
DNA plasma levels and urine excretion in patients with acute
PUUV infection. We aimed to evaluate the associations of plasma
cf-DNA levels with the clinical severity of the disease. We also
wanted to assess whether the excretion of cf-DNA is associated
with the severity of the infection or renal insufficiency. In addition
to measuring total cf-DNA levels directly in plasma and urine, we
carried out a qualitative high-sensitivity lab-on-a-chip DNA assay
to elucidate the appearance of cf-DNA in plasma and urine during
the course of the infection.
Materials and Methods
Patients
The study cohort consisted of 61 prospectively collected
consecutive adult patients with acute NE. The diagnosis of acute
PUUV infection was serologically confirmed in all cases [38]. The
patients were treated at the Tampere University Hospital
(Tampere, Finland) from September 2000 to December 2004.
The median patient age was 46 (range 22–77) years, and 44 (72%)
were males. We have previously studied IL-6 and CRP in 118 NE
patients [22], as well as IDO in 102 NE patients [23]. Forty-eight
of the patients in the present study were also included in the IL-6
and CRP study, and all 61 patients in the present study were also
included in the IDO study. We have also previously studied
complement activation as well as PTX3 in NE in the same cohort
of 61 patients [13,24]. Furthermore, 19 of the patients in the
present study were also included in studies examining the
activation of coagulation and fibrinolysis as well as platelet ligands
and endothelial involvement in NE [39–40].
The following diseases before NE were prevalent in 24 (39%)
patients: essential hypertension in eight; dyslipidemia in six; atrial
fibrillation in three; coronary artery disease, bronchial asthma,
hypothyreosis, chronic inflammatory bowel disease, and hyper-
plasia of the prostate in two patients each; diabetes mellitus, sick
sinus syndrome treated with pacemaker, Sjo¨gren’s syndrome,
mitral valve disease, epilepsy, fibromyalgia, sarcoidosis, multiple
sclerosis, operated atrial septal defect, and operated melanoma
were present in one patient each.
All subjects gave an informed consent before participation and
the study was approved by the Ethics Committee of Tampere
University Hospital.
Study protocol
All 61 patients were examined during the acute phase of NE. A
detailed past and current medical history was obtained, and a
careful physical examination was performed. Blood samples were
collected between 7:30–9:30 in the morning for up to five
consecutive days after hospitalization. They were used for the
analysis of plasma cf-DNA, PTX3, IL-6 (from 48 patients), CRP,
and creatinine, as well as serum kynurenine (Kyn) and tryptophan
(Trp) levels, and also for the blood cell counts. Other blood
samples were taken according to the clinical needs of the patient.
The nightly urine collection was performed during two
consecutive nights after hospitalization. The nightly collection
period was set from the time of the last voiding at bedtime until the
last voiding on rising. After completion, volume was measured and
timing was recorded for the collection period.
The highest and the lowest values of the various variables
measured during hospitalization for each patient were designated
as the maximum and minimum values.
One to three chest radiographs were obtained from 38 patients
(62%).
Fifty-three (87%) of the 61 patients were also studied at the out-
patient clinic four weeks after the hospital period. The plasma and
urine samples taken four weeks after the hospital treatment were
regarded and assessed as control/recovery samples.
Methods
Quantification analyses of plasma and urine cf-DNA
The cf-DNA analyses were performed afterwards from frozen
samples stored at 270uC. The amount of total cf-DNA was
determined directly in plasma and urine without any DNA
purification step, using the Quant-iTTM high-sensitivity DNA
assay kit and a QubitH fluorometer (Invitrogen, Carlsbad, CA,
USA) following the manufacturer’s instructions. Plasma samples
were analysed in duplicate and the mean of the two values was
used as the final value. The assessed intra-day variation
coefficients at the mean plasma cf-DNA levels of 0.673 mg/ml,
0.876 mg/ml and 1.59 mg/ml were 4.2%, 1.0% and 4.1%,
respectively. The corresponding inter-day variation coefficients
were 5.5%, 4.3% and 6.6%. Total cf-DNA in urine was
measured in 20/61 patients with quadruple measurements in
which the mean of the four values was used as the final value.
The assessed intra-day variation coefficients at the mean urine
levels of 0.307 mg/ml, 0.769 mg/ml and 1.13 mg/ml were 5.0%,
4.8% and 3.5%, respectively. The corresponding inter-day
variation coefficients were 10.0%, 6.5% and 10.2%. Timed
overnight urinary excretion of cf-DNA was calculated as follows:
(concentration6total volume)/(time span).
Extraction and qualitative analysis of cf-DNA in plasma
and urine
Qualitative analysis of plasma and urine cf-DNA was performed
for randomly selected 10 patients with and without renal
insufficiency (defined as maximum plasma creatinine .370 mmol/l
and maximum plasma creatinine ,125 mmol/l, respectively).
Plasma and urine cf-DNA was extracted using the NucleoSpinH
Plasma XS Kit (MACHEREY-NAGEL GmbH & Co., Du¨ren,
Germany), designed for isolation of low-molecular-weight (50–
Cell-Free DNA in Hantavirus Infection
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1000 bp) cf-DNA. Cf-DNA isolation was performed according to
the manufacturer’s instructions following the high-sensitivity proto-
col. Extracted cf-DNA samples were analyzed with the High
Sensitivity DNA assay kit and an Agilent 2100 Bioanalyzer equipped
with Expert 2100 software according to the manufacturer’s
instructions (Agilent Technologies Inc., Santa Clara, CA). Agilent
2100 Bioanalyzer uses a lab-on-a-chip technology to perform gel
electrophoresis; nucleic acids are separated analogously to a capillary
electrophoresis and normalized to a ladder and two DNA markers,
after which the software automatically calculates the size of each
band. For each plasma sample, the appearance and intensity of low-
molecular weight cf-DNA was estimated visually and graded as
follows: 1 = no visible cf-DNA or extremely weak band intensity,
2 = intermediate band intensity, 3 = strong band intensity. The
researcher responsible for analysing and grading the cf-DNA
samples was blinded for the clinical data of the patients. The
appearance of cf-DNA in urine was analyzed descriptively.
Plasma CRP and creatinine levels were analyzed using Cobas
Integra analyzer (F. Hoffman-La Roche Ltd, Basel, Switzerland).
Blood cell count was completed by hematological cell counters by
Bayer. Plasma IL-6 concentrations were determined as previously
described [21]. IDO level can be measured by determining the
ratio of Kyn to Trp in serum [41] by reverse-phase high
performance liquid chromatography (HPLC) as previously
described [42]. The Kyn/Trp ratio was calculated by relating
concentrations of Kyn to Trp. Plasma PTX3 determinations were
performed by using a commercially available human pentraxin-3
immunoassay (Quantikine, R&D Systems, Inc., Minneapolis,
MN), following the manufacturer’s instructions. Plasma IL-6 and
PTX3 as well as serum Kyn and Trp concentrations were
measured afterwards from frozen samples. All laboratory variables
mentioned above were determined at the Laboratory Center of
Pirkanmaa Hospital District.
Statistical Analyses
In order to describe the data, medians and ranges were given for
continuous variables and numbers and percentages for categorical
variables. Groups were compared using the Mann-Whitney U-
test. Categorical data were analyzed by the x2 test or the Fisher’s
exact test, as appropriate. Correlations were calculated by the
Spearman’s rank correlation test. Wilcoxon’s test was used to
compare two related samples. All tests were two-sided, and
statistically significant P-values are given. All analyses were made
with the SPSS (version 18) statistical software package.
Results
The clinical characteristics of the 61 patients are shown in
Table 1 and the laboratory variables in Table 2. None of the
patients was in clinical shock at the time of admission. Four
patients (7%) needed hemodialysis treatment during the hospital
stay. Eleven patients had pathologic findings in chest radiograph,
i.e. 29% of the 38 patients with radiograph performed. No deaths
occurred.
The maximum total plasma cf-DNA values taken during acute
NE were significantly higher than the control values taken after the
hospitalization period (median 1.33 mg/ml, range 0.94–3.29 mg/
ml vs. median 0.77 mg/ml, range 0.55–0.99 mg/ml, P,0.001).
Maximum urinary excretion of cf-DNA was not increased during
the acute phase of NE when compared with the control values
after the hospitalization (median 0.68 mg/min, range 0.34–
1.38 mg/min vs. median 0.62 mg/min, range 0.19–1.15 mg/ml,
P = 0.43). The control values were taken median 41 (range 18–83)
days after the onset of fever.
The maximum plasma cf-DNA levels correlated positively with
maximum blood leukocyte count (r= 0.388, P = 0.002), maximum
plasma PTX3 levels (r= 0.513, P,0.001), and the length of
hospital stay (r= 0.376, P = 0.003). There was also an inverse
correlation between maximum plasma cf-DNA levels and
minimum blood platelet count (r=20.297, P = 0.020). The
maximum plasma cf-DNA levels did not correlate with maximum
plasma creatinine levels or minimum urinary output (r = 0.101,
P = 0.436 and r=20.063, P = 0.636; respectively). Neither did the
maximum cf-DNA levels correlate with minimum hematocrit,
maximum plasma CRP, IL-6 or serum IDO levels (r =20.120,
P = 0.359; r=20.015, P = 0.907; r= 0.202, P = 0.168 and
r = 0.228, P = 0.077; respectively). There was no correlation
between plasma cf-DNA and age (r = 0.093, P = 0.477).
There was no significant difference in maximum plasma cf-
DNA levels between patients with normal or pathologic chest
radiograph, or between patients who needed hemodialysis
treatment and those who managed without hemodialysis. Also,
the plasma cf-DNA levels did not differ between men and women
(data not shown).
The maximum urinary excretion of cf-DNA did not correlate
with any of the variables reflecting severity of the disease, and it
did not correlate with age or maximum plasma cf-DNA, either
(data not shown).
Qualitative analysis of plasma cf-DNA revealed that during the
acute phase of the disease, in most patients cf-DNA displayed a
low-molecular weight appearance, corresponding to the size of
apoptotic DNA fragments (150–200 bp) (Figures 1A and 1B). This
phenomenon was observed in patients with and without renal
Table 1. Clinical data for 61 patients with Puumala hantavirus
infection.
Median Range
Age (years) 46 22–77
BMI (kg/m2) 25.1 19.8–35.7
Duration of fever before hospital
admission (days)
4 1–15
Duration of fever (days) 6 2–19
Length of hospital stay (days) 6 2–15
Urinary output min (ml/day) 1600 50–4940
BMI = body mass index, min =minimum, max =maximum
doi:10.1371/journal.pone.0031455.t001
Table 2. Laboratory data for 61 patients with Puumala
hantavirus infection.
Median Range
Creatinine max (mmol/l) 175 65–1285
Platelets min (10E9/L) 68 9–238
Hematocrit min 0.36 0.25–0.43
Leukocytes max (10E9/L) 9.9 3.9–31.2
CRP max (mg/l) 69.2 16.7–269.2
IL-6 max (pg/ml) (n = 48) 11.5 1.3–96.6
IDO max (mmol/mmol) 212.3 46.6–3679.2
Min =minimum, Max =maximum, CRP =plasma C-reactive protein, IL-
6 = plasma inteleukin-6, IDO= serum kynurenine/tryptophan ratio.
doi:10.1371/journal.pone.0031455.t002
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insufficiency. The visually graded maximum cf-DNA band
intensity correlated positively with the maximum quantity of total
plasma cf-DNA (r= 0.513, P = 0.021). However, the maximum cf-
DNA band intensity did not correlate with any of the clinical or
laboratory parameters. In control samples, which were taken four
weeks after the hospital period, the low-molecular weight cf-DNA
band was either completely absent or markedly weakened in all
patients (Figures 1A and 1B).
Qualitative analysis of urine-cf-DNA revealed that in contrast to
plasma, no distinguishable low-molecular weight (150–200 bp)
Figure 1. Qualitative analysis of plasma cf-DNA in 10 patients with maximum plasma creatinine .370 mmol/l (A) and 10 patients
with maximum plasma creatinine ,125 mmol/l (B) after NucleoSpinH Plasma XS kit extraction. Analyses were performed with Agilent’s
High Sensitivity Lab-on-a-chip DNA assay. Green lines indicate the low weight (35 base pairs (bp)) DNA marker and purple lines the high weight
(10 380 bp) DNA marker. The intensity of low-molecular weight cf-DNA band was graded as follows: 1 = no visible cf-DNA or weak band intensity,
2 = intermediate band intensity, 3 = strong band intensity.
doi:10.1371/journal.pone.0031455.g001
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pattern of cf-DNA was detected during the acute phase of the
disease, with the exception of two patients with renal insufficiency
(patients no 5 and 7 with maximum plasma creatinine
.370 mmol/l) (Figure 2). In addition, two patients (no 3 and 20)
had random-sized cf-DNA fragments in their control urine
samples (Figure 2). The tracings of patients no 11 and 14 are
shown as examples of the 16 patients who had no findings in the
urinary cf-DNA fragment analyses (Figure 2).
Discussion
The data presented here show that plasma cf-DNA levels are
elevated during acute PUUV infection. The cf-DNA values
measured during the acute phase were markedly higher than the
values measured after the hospitalization. Previously, in bacter-
emia patients the median maximum cf-DNA levels were 2.03 mg/
ml in nonsurvivors and 1.26 mg/ml in survivors [34]. In the
present study, the median maximum plasma cf-DNA levels
(1.33 mg/ml) were close the level of survived bacteremia patients.
In the study presented here, the total plasma cf-DNA levels did not
correlate with the severity of renal insufficiency. However, there
was an inverse correlation between plasma cf-DNA level and
blood platelet count. In addition, plasma cf-DNA levels correlated
positively with blood leukocyte count and the length of hospital
stay, which is probably one of the best variables reflecting the
overall severity of the disease as all patients fully recovered. Plasma
cf-DNA levels also correlated with plasma PTX3 levels. This is
logical as PTX3 contributes to the opsonization and clearance of
Figure 2. Qualitative analysis of urine cf-DNA after NucleoSpinH Plasma XS kit extraction. Analyses were performed with Agilent’s High
Sensitivity Lab-on-a-chip DNA assay. Green lines indicate the low weight (35 base pairs (bp)) DNA marker and purple lines the high weight
(10 380 bp) DNA marker. During the acute phase of the disease low-molecular weight (150–200 bp) pattern of cf-DNA was detected only in patients
no 5 and 7, while patients no 3 and 20 had random-sized cf-DNA fragments in their control urine samples. Data from patients no 11 and 14 are
depicted as examples of the 16 subjects who had no findings in the urinary cf-DNA fragment analyses.
doi:10.1371/journal.pone.0031455.g002
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apoptotic or necrotic cells [43], which are regarded as the origin of
cf-DNA. In contrast, urine maximum cf-DNA excretion did not
correlate with any clinical or laboratory parameters or maximum
plasma cf-DNA.
Qualitative analysis of plasma cf-DNA revealed that, during the
acute phase of infection, cf-DNA displayed a predominance of
low-molecular weight and apoptotic (150–200 bp) appearance,
whereas after recovery, such cf-DNA pattern was not observed in
any of the patients. It is thus likely that the detected low-molecular
weight cf-DNA originated from apoptotic cells in the course of the
acute phase of the disease. In fact, results from a recent study in
PUUV infected patients suggest that acute hantavirus infection is
associated with immune reaction-induced renal tissue damage
[26]. Moreover, the observed correlation between maximum total
plasma cf-DNA concentration and the low-molecular weight cf-
DNA band intensity supports the hypothesis that the increase in
plasma cf-DNA is due to apoptosis. Notably, NE is a general
infection and thus the low-molecular weight DNA fragments could
be derived from a variety of affected tissues. Similar results in
qualitative cf-DNA pattern have recently been observed in
bacteremia patients [34]. However, in the current study, the
plasma cf-DNA band intensity was not associated with the level of
renal function or clinical picture of the disease. We did not detect
any qualitative patterns in urine cf-DNA that could be attributed
to the disease severity, either. Nevertheless, two patients with renal
insufficiency had a clear low-molecular weight cf-DNA band in the
urine during the acute phase of the disease, potentially indicating
increased apoptosis in the renal system.
The observation that the correlates for maximal total urinary cf-
DNA excretion were different from those of the maximum plasma
cf-DNA concentration suggest that the amount of cf-DNA in urine
may not be clinically relevant and the excretion of cf-DNA does
not reflect the degree of inflammation in the kidneys in acute NE.
Our findings are corroborated by previous results which have
demonstrated that in hematopoietic stem cell transplant patients,
the quantity of donor-derived cf-DNA in urine does not correlate
with that of plasma and that the predominant cf-DNA fragment
size differs between plasma and urine [44–45]. A similar
phenomenon regarding the DNA fragment size discrepancy
between plasma and urine cf-DNA has also been observed in
pregnant women [46]. In fact, urinary cf-DNA is likely to consist
of a heterogeneous mixture of cf-DNA fragments originating from
dying cells in the renal system and from the pool of plasma
circulating cf-DNA. The former is supported by the observation
that patients with urinary tract infection have elevated urine cf-
DNA levels [44], whereas the latter has been demonstrated in
colorectal cancer patients who displayed tumor-derived mutated
K-ras sequences in the transrenal urine cf-DNA [47–48]. Likewise,
Y-chromosomal DNA sequences have been detected in the urine
of pregnant women carrying male fetuses [44]. Based on animal
studies, however, it has been estimated that only 0.5–2% of the
circulating DNA passes through the kidneys and is excreted into
the urine in a polymeric form [44,49]. The exact mechanism by
which cf-DNA crosses the glomerular basement membrane is
currently unknown, yet the maximum urinary excretion of cf-
DNA is anticipated to be influenced by renal function although
our current results do not seem to support this hypothesis.
Previously cf-DNA has been investigated in a variety of clinical
conditions. However, studies concerning infections other than
sepsis are scarce. In septic patients, there are studies showing
elevated cf-DNA levels that also predict outcome [32,34,50–51].
In trauma patients, cf-DNA predicted inflammatory second hit
and sepsis [52]. In febrile patients, cf-DNA showed prognostic
value in assessing the probability and severity of infection and
sepsis [53]. In viral infections, elevated levels of cf-DNA have been
found in patients with occult hepatitis B [54].
In conclusion, the plasma levels of cf-DNA are elevated during
acute PUUV infection and correlate with the apoptotic band
intensity. The total plasma cf-DNA concentration correlates with
some variables reflecting the severity of the disease. The urinary
excretion of cf-DNA does not reflect the degree of inflammation in
the kidney.
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